For the Inventor, By the Inventor

Enter assignee name

Monmouth Junction, NJ, United States of America

Cytosorbents Corporation

USPTO Granted Patents = 30

CIPO Patents = 27

EPO Patents = 10

Trademarks = 14

Forward Citations = 37

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Thomas D Golobish (24 out of 28 patents)

Vincent J Capponi (22 out of 24 patents)

Phillip Chan (19 out of 19 patents)

4. Wei-Tai Young (15 out of 16 patents)

5. Humayra Begum Ali (12 out of 12 patents)

6. Tamaz Guliashvili (8 out of 11 patents)

7. Andrew Scheirer (8 out of 8 patents)

8. Maryann Gruda (7 out of 10 patents)

9. Pamela O'Sullivan (6 out of 6 patents)

10. James A Brady (4 out of 9 patents)

11. Vadim Davankov (4 out of 24 patents)

12. Ludmila Pavlova (4 out of 17 patents)

13. Frank M Norris (4 out of 7 patents)

14. Peter J Quartararo, Jr (4 out of 7 patents)

15. Jamie A Salsberg (4 out of 7 patents)

30 patents: Sort by Forward Citations

1. 12280196 - Methods of using polymers (2025-04-21),

2. 12208116 - Multi-functional hemocompatible porous bead sorbent for removing protein based toxins and potassium from biological fluids (2025-01-28),

3. 12121879 - Crosslinked polysaccharide based absorbents for removal of anti-A and/or anti-B antibodies from human plasma and whole blood (2024-10-22),

4. 12076474 - Method of treating traumatic brain injury (2024-09-03),

5. 11969535 - Connector assembly and methods of use (2024-04-30),

6. 11826724 - Use of a hemocompatible porous polymer bead sorbent for removal of endotoxemia-inducing molecules (2023-11-28),

7. 11752250 - Hemocompatibility modifiers for cross-linked polymeric material (2023-09-12),

8. 11723916 - Multi-functional hemocompatible porous polymer bead sorbent for removing protein based toxins and potassium from biological fluids (2023-08-15),

9. 11602585 - Methods for reducing contamination in a biological substance (2023-03-14),

10. 11202855 - Methods for removal of toxins from blood using an extracorporeal circuit comprised of a hollow-fiber filter module and polymer sorbent in combination (2021-12-21),

11. 11065600 - Use of a hemocompatible porous polymer bead sorbent for removal of endotoxemia-inducing molecules (2021-07-20),

12. 11058715 - Method of treating inflammation (2021-07-13),

13. 11040061 - Multi-functional hemocompatible porous polymer bead sorbent for removing protein based toxins and potassium from biological fluids (2021-06-22),

14. 11020521 - Hemocompatibility modifiers for cross-linked polymeric material (2021-06-01),

15. 10967001 - Method of treating inflammation (2021-04-06),

Cytosorbents Corporation is a publicly-traded critical care immunotherapy leader that specializes in the development and commercialization of innovative medical devices to treat life-threatening conditions. The company's flagship product, CytoSorb, is a unique blood purification technology designed to remove harmful substances from the bloodstream. With applications in multiple critical care areas like sepsis, cytokine storm, and acute respiratory distress syndrome (ARDS), Cytosorbents Corporation aims to improve survival rates and outcomes for critically ill patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

30 Patents

#4 in Monmouth Junction, NJ

#440 in New Jersey

#10,854 in US

#21,168 in the World

Monmouth Junction, NJ, United States of America

Cytosorbents Corporation

Forward Citations = 37

41 inventors:

Thomas D Golobish (24 out of 28 patents)

Vincent J Capponi (22 out of 24 patents)

Phillip Chan (19 out of 19 patents)

4. Wei-Tai Young (15 out of 16 patents)

5. Humayra Begum Ali (12 out of 12 patents)

Please report any incorrect information to support@idiyas.com

Loading…